Kaplan-Meier estimated of overall survival (OS) for SVM1, SVM2 and SVM3 models identified high and low risk to death subgroups in both testing set and overall patients.

<p>For SVM1 model (A), a significant survival disadvange was observed for the high risk to death subgroup, which was identified by SVM1 model, in testing set (left panel) and overall patients (right panel). For SVM2 (B) and SVM3 model (C), a statistically OS difference was shown between high and low risk to death subgroups, which was indentified respectively by SVM2 and SVM3 model, in testing set (left panel) and overall patients (right panel).</p

Kaplan–Meier survival analysis of baseline LMR in NPC patients.

<p>A. OS curves for LMR; B. DFS curves for LMR; C. DMFS curves for LMR; D. LRRFS curves for LMR. LMR, lymphocyte-to-monocyte ratio; NPC, nasopharyngeal carcinoma; OS, overall survival; DFS, disease-free survival; DMFS, distant metastasis-free survival; LRRFS, loco-regional recurrence-free survival.</p

Patient characteristics.

<p>Abbreviation: IC/RT, Induction chemotherapy+radiotherapy; IC/CRT, Induction chemotherapy+concurrent chemoradiotherapy.</p

Multivariate Cox Regression Analysis of the SVM1, SVM2 and SVM3 Models in Testing Set and Overall Patients.

<p>Multivariate Cox Regression Analysis of the SVM1, SVM2 and SVM3 Models in Testing Set and Overall Patients.</p

Immunohistochemical staining of tissue biomarkers in locally advanced NPC.

<p>The panel displayed the representative expression of 37 molecular biomarkers in tumor zone for locally advanced NPC (original magnification, ×400).</p

ROC curves plotted for patient outcome, using 38 tissue molecule expression scores, 3 serological biomarkers levels and SVM models, in training set (A), testing set (B) and overall patients (C).

<p>In training set (A), at each immunohistochemical staining score of 38 tissue molecules and 3 serological biomarkers, the sensitivity and specificity for the outcome being studied were plotted, thus generating a ROC curve. The score, that closest to the point with both maximum sensitivity and specificity (0.0, 1.0), was selected as the cutoff point for further analysis.</p

Univariate analysis of prognostic factors for patients with nasopharyngeal carcinoma.

<p>Abbreviation: OS  =  Overall Survival; DFS  =  Disease-Free Survival; DMFS  =  Distant Metastasis-Free Survival; LRRFS  =  Loco-Regional Recurrence-Free Survival; CRT  =  chemoradiotherapy; RT =  radiotherapy; LMR  =  lymphocyte-to-monocyte ratio; HR  =  Hazard Ratio, derived from COX proportional hazard model.</p

Multivariate analysis of independent prognostic factors for patients with nasopharyngeal carcinoma (n = 1547).

<p>Abbreviation: OS  =  Overall Survival; DFS  =  Disease-Free Survival; DMFS  =  Distant Metastasis-Free Survival; LRRFS  =  Loco-Regional Recurrence-Free Survival; CRT  =  chemoradiotherapy; RT  =  radiotherapy; LMR  =  lymphocyte-to-monocyte ratio; HR  =  Hazard Ratio, derived from COX proportional hazard model. In this analysis, T status, N status and tumor stage were divided into two groups. For T status: T1-2 and T3-4; for N status:N0-1 and N2-3; for tumor stage: I–II and III–IV.</p

Kaplan–Meier survival analysis of baseline lymphocyte count (LY) in NPC patients.

<p>A. OS curves for LY; B. DFS curves for LY; C. DMFS curves for LY; D. LRRFS curves for LY. LY, lymphocyte count; NPC, nasopharyngeal carcinoma; OS, overall survival; DFS, disease-free survival; DMFS, distant metastasis-free survival; LRRFS, loco-regional recurrence-free survival.</p

Kaplan–Meier survival analysis of baseline monocyte count (MO) in NPC patients.

<p>A. OS curves for MO; B. DFS curves for MO; C. DMFS curves for MO; D. LRRFS curves for MO. MO, monocyte count; NPC, nasopharyngeal carcinoma; OS, overall survival; DFS, disease-free survival; DMFS, distant metastasis-free survival; LRRFS, loco-regional recurrence-free survival.</p